AI vs. medical review accuracy in clinical trial translation services

Pharmaceutical and medtech teams choose clinical trial translation services for one of two reasons: speed or regulatory readiness. Sometimes both. But the tools used to deliver those two outcomes are not the same.

General-purpose AI translation — the DeepLs and GPT-4s of the world — has changed how fast a first draft can be produced. For an internal team memo or a literature review, it is often good enough. For an informed consent form, a protocol amendment, or a clinical study report bound for ANVISA, COFEPRIS, or ANMAT, good enough is not a category.

This guide compares the two approaches side by side, with a focus on what matters for Phase III documentation: accuracy that holds up under medical review, traceability that holds up under audit, and accountability that a regulatory body can point to.

Large language models and neural machine translation engines are trained on enormous corpora. They excel at fluency, grammar, and preserving the surface structure of a sentence. For a press release or a patient-facing brochure, that is often sufficient.

The problem is not that these systems make mistakes. The problem is that they cannot tell which mistakes matter. A model will confidently translate "dose escalation" into a grammatically correct Spanish sentence that a regulator would accept — and it will do the same for a dosage-unit error that a regulator would reject. Both look the same to the model because both are statistically plausible.

There is no medical license behind the output. No named clinician who can explain why a term was chosen. No audit trail that maps a questionable phrase back to a source decision. For clinical trial translation services, that absence is the risk.

Medical review is not proofreading. It is a clinical judgment layer applied to a translated document by a physician or scientist who understands the therapeutic area, the target country, and the regulatory environment the submission will enter.

A reviewer asks different questions than a model does. Is the dosing interval preserved across linguistic variants? Does the Spanish equivalent of "adverse event" carry the same regulatory weight in Brazil as it does in Mexico? Is the patient population description consistent with the protocol synopsis, and if not, is it a translation choice or a clinical discrepancy?

Most importantly, the reviewer's name is attached to the decision. That is what makes the output auditable. A regulator can ask, "Who decided this phrasing?" and there is a person, a credential, and a rationale.

Phase III is where a sponsor's translation process stops being an operational task and becomes a liability surface. Every document in the submission package — protocol, investigator brochure, consent forms, case report forms, study reports — can be inspected by a regulator who reads the local language.

A regulator will not ask whether the document was produced quickly. They will ask whether the translation is faithful to the source, whether the patient-facing language is ethically sound, and whether the risk-benefit wording is consistent across countries. Those questions require clinical judgment, not statistical plausibility.

General-purpose AI can get a sponsor 70% of the way there in 10% of the time. The remaining 30% is where submissions are delayed, questioned, or rejected. That is the part medical review owns.

In Latin America, regulators expect translated clinical documents to be accurate, consistent, and traceable. Accuracy is not a subjective standard. It means that a medically trained reviewer in the target country can read the document and confirm it matches the clinical intent of the source.

Consistency means the same adverse event, device component, or dosing instruction is described the same way across the protocol, consent form, and investigator brochure. Traceability means that when a reviewer changes a term, the change is recorded, the reason is recorded, and the source document is referenced.

AI does not produce compliance artifacts. It produces text. Medical review turns that text into a defensible document.

We do not pitch AI as a replacement for clinical judgment. We use it as the first step in a workflow that is designed to end with a named medical reviewer saying the document is ready for submission.

In practice, that means AI generates the first draft, a controlled glossary enforces preferred terminology, and an MD or PhD reviewer in the target country reviews for medical accuracy, regulatory phrasing, and country-specific convention. The result is faster than a purely human workflow and more defensible than a purely AI workflow.